Figulla H.R.,Friedrich - Schiller University of Jena |
Webb J.G.,University of British Columbia |
Lauten A.,Charité - Medical University of Berlin |
Feldman T.,NorthShore University HealthSystem Evanston
European Heart Journal | Year: 2016
The transcatheter valve technology pipeline has started as simple balloon valvuloplasty for the treatment of stenotic heart valves and evolved since the year 2000 to either repair or replace heart valves percutaneously with multiple devices. In this review, the present technology and its application are illuminated and a glimpse into the near future is dared from a physician's perspective. The Author 2016.
PubMed | NorthShore University HealthSystem Evanston, Northwestern University and University of Chicago
Type: Journal Article | Journal: Sexual medicine | Year: 2015
The aim of this study was to examine the relationship between sexual dysfunction, repeat biopsies and other demographic and clinical factors in men on active surveillance (AS).Patient-reported outcomes (PROs) measures were administered at enrollment and every 6 months to assess quality of life (QOL), psychosocial and urological health outcomes. Using mixed-effects models, we examined the impact of repeat biopsies, total number of cores taken, anxiety, age, and comorbidity on sexual function over the first 24 months of enrolling in AS.PROs included the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Sexual Function (SF) subscale, the American Urological Association-Symptom Index (AUA-SI), and the Memorial Anxiety Scale for Prostate Cancer (MAX-PC).At enrollment (n=195), mean age was 66.56.8 with a mean EPIC-26 SF score of 61.430.4. EPIC-26 SF scores steadily decreased to 53.930.7 at 24 months (P<0.01). MAX-PC scores also progressively decreased over time (P=0.03). Factors associated with lower EPIC-26 scores over time included age, unemployed status, diabetes, coronary artery disease, and hypertension (all P<0.05). Higher prostate-specific antigen (PSA) was associated with a more rapid decline in EPIC-26 SF over time (P=0.03). In multivariable analysis, age, diabetes, and PSAtime interaction remained significant predictors of diminished sexual function. Anxiety, number of biopsies, and total cores taken did not predict sexual dysfunction or change over time in our cohort.Men on AS experienced a gradual decline in sexual function during the first 24 months of enrollment. Older age, PSAtime, and diabetes were all independent predictors of diminished sexual function over time. Anxiety, AUA-SI, the number of cores and the number of biopsies were not predictors of reduced sexual function in men in AS.